Evidence map›Paper›PMID 26503110›Full record

ReviewProstate cancer and prostatic diseases2016

Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

V Mouraviev, B Lee, V Patel, D Albala, T E B Johansen, A Partin, A Ross, R J Perera

Abstract readReview
PubMed Publisher
In one paragraph

Review in Prostate cancer and prostatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 102 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

V MouravievGlobal Robotics Institute, Florida Hospital Celebration Health, Celebration, FL, USA.
B LeeDepartment of Integrative Metabolism, Sanford-Burnham Medical Research Institute, Orlando, FL, USA.
V PatelGlobal Robotics Institute, Florida Hospital Celebration Health, Celebration, FL, USA.
D AlbalaAssociated Medical Professionals of New York, Syracuse, NY, USA.
T E B JohansenDepartment of Urology, Oslo University Hospital, Oslo, Norway.
A PartinBrady Urology Institute, John Hopkins School of Medicine, Baltimore, MD, USA.
A RossBrady Urology Institute, John Hopkins School of Medicine, Baltimore, MD, USA.
R J PereraDepartment of Integrative Metabolism, Sanford-Burnham Medical Research Institute, Orlando, FL, USA.
AdventHealth Celebration · USSanford Burnham Prebys Medical Discovery Institute · USOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long noncoding RNAs (lncRNAs) are non-protein-coding RNA species. lncRNAs are dysregulated in many diseases including PCa and are emerging as major players in cancer development. lncRNAs have several features that make then suitable as both biomarkers and therapeutics, and lncRNAs regulate critical cancer hallmarks in prostate epithelial cells including proliferation and survival.

methodsThe PubMed database was searched using the terms 'long noncoding RNA', 'biomarker' and 'prostate cancer'. Known lncRNAs implicated as biomarkers and potential therapeutic targets in PCa are reviewed.

resultsWe comprehensively review several lncRNAs with potential as biomarkers for PCa. lncRNAs including PCA3, PCATs, SChLAP1, SPRY4-IT1 and TRPM2-AS are upregulated in PCa and are cancer specific; they are, therefore, attractive lead candidate biomarkers for clinical application. Several lncRNA therapeutics are currently being investigated by several companies for the treatment of various cancers including PCa. Small interfering RNAs, antisense oligonucleotides, ribozymes, deoxyribozymes and aptemers are few promising technologies for future lncRNA bases therapeutics.

conclusionlncRNA expression is altered in cancer. Aberrant regulation promotes tumor formation, progression and metastasis. lncRNAs can use as tumor markers for PCa and may be attractive novel therapeutic targets for the diagnosis and treatment of PCa.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticHumansMaleMolecular Targeted TherapyPrognosisProstatic NeoplasmsRNA, Long NoncodingBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID26503110
OpenAlexW1867424522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.